2017
Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis
Korman BD, Marangoni RG, Hinchcliff M, Shah SJ, Carns M, Hoffmann A, Ramsey‐Goldman R, Varga J. Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis. Arthritis & Rheumatology 2017, 69: 2062-2068. PMID: 28651038, PMCID: PMC5748338, DOI: 10.1002/art.40193.Peer-Reviewed Original ResearchMeSH KeywordsAdiponectinAdultAgedAutoantibodiesComplement Factor DCytokinesFemaleGene Expression ProfilingHumansHypertension, PulmonaryLeptinMaleMiddle AgedNatriuretic Peptide, BrainNicotinamide PhosphoribosyltransferaseOdds RatioPolymorphism, Single NucleotideResistinScleroderma, DiffuseScleroderma, LimitedConceptsSSc-related pulmonary arterial hypertensionPulmonary arterial hypertensionSystemic sclerosisAdipokine levelsComplement pathway activationAdipsin levelsArterial hypertensionLimited cutaneous systemic sclerosisB-type natriuretic peptidePathway activationSerum adipokine levelsCutaneous systemic sclerosisLevels of adiponectinGene single nucleotide polymorphismsAdipose tissue biologyTissue-derived markersAdipokine balanceAutoantibody statusPulmonary functionSSc patientsAdipocyte dysfunctionClinical featuresPathogenic linkClinical manifestationsNatriuretic peptideA novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis
Taroni JN, Greene CS, Martyanov V, Wood TA, Christmann RB, Farber HW, Lafyatis RA, Denton CP, Hinchcliff ME, Pioli PA, Mahoney JM, Whitfield ML. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Medicine 2017, 9: 27. PMID: 28330499, PMCID: PMC5363043, DOI: 10.1186/s13073-017-0417-1.Peer-Reviewed Original ResearchConceptsDisease-associated signaturesFunctional genomic networksGene expression signaturesPulmonary fibrosisAutoimmune diseasesDisease processMulti-organ autoimmune diseaseDistinct underlying pathologyPro-fibrotic macrophagesInternal organ involvementPulmonary arterial hypertensionExpression signaturesSkin of patientsInnate immune systemWilcoxon rank sum testGenomic networksRank sum testBackgroundSystemic sclerosisArterial hypertensionOrgan involvementSystemic sclerosisUnderlying pathologyLung microenvironmentSkin fibrosisFibrotic genes
2016
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech TM, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TAJ, Molitor JA, Preston IR, Schiopu E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, Zamanian RT. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clinical And Experimental Rheumatology 2016, 35 Suppl 106: 106-113. PMID: 27908301.Peer-Reviewed Original ResearchConceptsB-type natriuretic peptideNT-proBNP levelsPg/mLSSc-PHNT-proBNPPulmonary hypertensionSSc patientsSystemic sclerosisNatriuretic peptideBaseline B-type natriuretic peptideMedian B-type natriuretic peptideSystemic sclerosis-associated pulmonary hypertensionMulticenter prospective cohortNT-proBNP groupNatriuretic peptide levelsRight ventricular dysfunctionPredictors of mortalityPulmonary arterial hypertensionPredictors of progressionAssessment of patientsBaseline creatinineSSc-PAHArterial hypertensionPAH patientsVentricular dysfunctionMolecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis
Hinchcliff M, Whitfield M. Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis. 2016, 657-670. DOI: 10.1007/978-3-319-31407-5_49.Peer-Reviewed Original ResearchSystemic sclerosisPatient subsetsProgressive interstitial lung diseaseDiffuse cutaneous systemic sclerosisAppropriate patient subsetsScleroderma renal crisisCutaneous systemic sclerosisInvestigator-initiated trialPulmonary arterial hypertensionSubset of patientsDifferent patient subsetsInterstitial lung diseaseDifferent pathophysiological processesMolecular pathwaysPrecision medicineGene expression subsetsT lymphocyte activationUninvolved skin samplesInflammatory subsetRenal crisisSSc complicationsArterial hypertensionMycophenolate mofetilClinical improvementOrgan involvement
2015
Survival in systemic sclerosis–pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry
Hinchcliff M, Khanna S, Hsu VM, Lee J, Almagor O, Chang RW, Steen V, Chung L, Investigators T. Survival in systemic sclerosis–pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. Seminars In Arthritis And Rheumatism 2015, 45: 309-314. PMID: 26210782, PMCID: PMC4656087, DOI: 10.1016/j.semarthrit.2015.06.011.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionPulmonary Hypertension AssessmentSerum autoantibodiesRecognition of OutcomesScleroderma RegistryArterial hypertensionScl-70Hypertension assessmentAutoantibody groupsSystemic sclerosis-pulmonary arterial hypertensionSocial Security Death IndexKaplan-Meier survival estimatesSurvival estimatesIncident systemic sclerosisSSc disease durationSSc-PAH patientsRight heart catheterizationRisk of deathProportional hazards modelClinical laboratoriesElectronic medical recordsMedian followSSc-PAHAutoantibody statusHeart catheterizationA candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosis
Marangoni RG, Korman BD, Allanore Y, Dieude P, Armstrong LL, Rzhetskaya M, Hinchcliff M, Carns M, Podlusky S, Shah SJ, Ruiz B, Hachulla E, Tiev K, Cracowski JL, Varga J, Hayes MG. A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosis. Arthritis Research & Therapy 2015, 17: 128. PMID: 25986483, PMCID: PMC4437446, DOI: 10.1186/s13075-015-0641-2.Peer-Reviewed Original ResearchConceptsSystemic sclerosisDiscovery cohortSingle nucleotide polymorphismsPathogenesis of SScNuclear receptor peroxisome proliferator-activated receptor gammaPeroxisome proliferator-activated receptor gammaPotent anti-fibrotic effectsPulmonary arterial hypertensionProliferator-activated receptor gammaAnti-fibrotic effectsRole of PPARGene single nucleotide polymorphismsReceptor gamma geneSSc cohortArterial hypertensionSSc patientsClinical parametersValidation cohortClinical associationsEuropean cohortReceptor gammaPPARG variantsDisease severityIntronic single nucleotide polymorphismC allele
2014
Antinuclear antibody-negative systemic sclerosis
Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, Mayes MD. Antinuclear antibody-negative systemic sclerosis. Seminars In Arthritis And Rheumatism 2014, 44: 680-686. PMID: 25578738, PMCID: PMC4447614, DOI: 10.1016/j.semarthrit.2014.11.006.Peer-Reviewed Original ResearchConceptsANA-negative groupANA-negative patientsPulmonary arterial hypertensionAntinuclear antibodiesSSc patientsDiffuse cutaneous involvementLower gastrointestinal involvementNegative antinuclear antibodyRight heart catheterizationScleroderma Family RegistrySSc-related antibodiesRodnan skin scoreSystemic sclerosis patientsANA-positive patientsRenal crisisVasculopathic manifestationsCause mortalityCutaneous involvementGastrointestinal involvementArterial hypertensionChart reviewClinical characteristicsHeart catheterizationMale patientsSkin scoreDevelopment of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study
Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, Silver R, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Alkassab F, Steen VD. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Seminars In Arthritis And Rheumatism 2014, 44: 55-62. PMID: 24709277, DOI: 10.1016/j.semarthrit.2014.03.002.Peer-Reviewed Original ResearchConceptsSystolic pulmonary arterial pressureRight heart catheterizationExercise-induced hypoxiaPulmonary hypertensionPulmonary arterial hypertensionPulmonary function testingSystemic sclerosisCohort studyDisease durationHigher systolic pulmonary arterial pressureProspective longitudinal cohort studyFVC/DLcoNew pulmonary hypertensionPulmonary Hypertension AssessmentDiffusion lung capacityPulmonary arterial pressureOngoing prospective studyKaplan-Meier survivalHigh-risk populationKaplan-Meier estimatesLongitudinal cohort studyHigh-risk factorsRecognition of OutcomesPFT criteriaPH patientsSurvival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry
Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, Derk C, Fischer A, Frech T, Furst DE, Gomberg‐Maitland M, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA, Molitor JA, Preston IR, Schiopu E, Shapiro L, Silver R, Simms R, Varga J, Gordon JK, Steen VD. Survival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry. Arthritis Care & Research 2014, 66: 489-495. PMID: 23983198, DOI: 10.1002/acr.22121.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionPulmonary Hypertension AssessmentCumulative survival rateRecognition of OutcomesSurvival rateScleroderma RegistryArterial hypertensionSSc patientsHypertension assessmentRoutine screeningWorld Health Organization group I PAHSystemic sclerosis associated pulmonary arterial hypertensionGroup I pulmonary arterial hypertensionSSc-associated pulmonary arterial hypertensionIncident pulmonary arterial hypertensionSSc centersRight-sided heart catheterizationDefinite pulmonary hypertensionIncident systemic sclerosisPredictors of mortalityMonths of enrollmentHeart catheterizationPAH diagnosisProspective registryPulmonary hypertension
2011
Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population
Hinchcliff M, Fischer A, Schiopu E, Steen VD. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population. The Journal Of Rheumatology 2011, 38: 2172-2179. PMID: 21844142, PMCID: PMC3230328, DOI: 10.3899/jrheum.101243.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionIncident pulmonary hypertensionPulmonary hypertensionSystemic sclerosisHigh riskBaseline characteristicsDevelopment of PAHEstimated right ventricular systolic pressureIncident pulmonary arterial hypertensionLeft-side heart diseaseRight ventricular systolic pressureCarbon monoxide diffusing capacityPAH-specific therapyPulmonary Hypertension AssessmentRight heart catheterizationPulmonary venous hypertensionVentricular systolic pressureHigh-risk subjectsInterstitial lung diseaseRecognition of OutcomesSSc-PAHArterial hypertensionHeart catheterizationVenous hypertensionSSc patients
2008
Systemic sclerosis/scleroderma: a treatable multisystem disease.
Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. American Family Physician 2008, 78: 961-8. PMID: 18953973.Peer-Reviewed Original ResearchConceptsInternal organ involvementSystemic sclerosisOrgan involvementRaynaud's phenomenonEndothelin-1 receptor blockerChronic connective tissue diseaseEnd-organ dysfunctionEnzyme inhibitor therapyHigh-dose corticosteroidsScleroderma renal crisisPulmonary arterial hypertensionPulmonary function testingConnective tissue diseaseDisease-modifying therapiesDistinct clinical subsetInternal organ dysfunctionOrgan-specific manifestationsPhosphodiesterase-5 inhibitorsMiddle-age womenOptimal patient careWidespread microvascular damageRenal crisisArterial hypertensionDigital ulcersLifestyle modification